Tumors of female reproductive system

Опухоли женской репродуктивной системы

1994-40981999-8627

Publishing House ABV Press

365

10.17650/1994-4098-2008-0-3-54-57

MAMMOLOGY. PHARMACOTHERAPY

МАММОЛОГИЯ. ФАРМАКОТЕРАПИЯ

Adjuvant endocrinotherapy of breast cancer (part I)

ВОЗМОЖНОСТИ АДЪЮВАНТНОЙ ЭНДОКРИННОЙ ТЕРАПИИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ (часть I)

Dobrovolskaya

N. Yu.

Добровольская

Н. Ю.

Russian Federation

Vozniy

E. K.

Возный

Э. К.

Russian Federation

Bichkov

Yu. M.

Бычков

Ю. М.

Russian Federation

ФГУ Российский научный центр рентгенорадиологии Росмедтехнологий, Москва

16082008

54571709201417092014

2008

https://ojrs.abvpress.ru/ojrs/article/view/365

Adjuvant endocrinotherapy of breast cancer (part I)

ВОЗМОЖНОСТИ АДЪЮВАНТНОЙ ЭНДОКРИННОЙ ТЕРАПИИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ (часть I)

1. Anderson W.F., Chatterjee N., Ershler W.B., Brawley O.W. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002;76:27—36.

Anderson W.F., Chatterjee N., Ershler W.B., Brawley O.W. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002;76:27—36.

2. EBCTCG. Lancet 1996;348:1189—96.

EBCTCG. Lancet 1996;348:1189—96.

3. Namer M. et al. New directions in hormone therapy for metastatic breast cancer. Ann Oncol 2002;13(Suppl 5):38. Abstr. 135 and poster.

Namer M. et al. New directions in hormone therapy for metastatic breast cancer. Ann Oncol 2002;13(Suppl 5):38. Abstr. 135 and poster.

4. Castiglione-Gertsch M., O’Neill A., Gelber R.D. et al. Is the addition of adju- vant chemotherapy always necessary in node negative (N—) pre/perimenopausal breast cancer patients who receive gosere- lin: first results of IBCSG trial VIII. Proc ASCO 2002;21:38a. Abstr. 149.

Castiglione-Gertsch M., O’Neill A., Gelber R.D. et al. Is the addition of adju- vant chemotherapy always necessary in node negative (N—) pre/perimenopausal breast cancer patients who receive gosere- lin: first results of IBCSG trial VIII. Proc ASCO 2002;21:38a. Abstr. 149.

5. Celio L., Bajetta E., Toffolatti L. et al. Ovarian ablation for premenopausal early-stage breast cancer: an update. Tumori 2000;86:191—4.

Celio L., Bajetta E., Toffolatti L. et al. Ovarian ablation for premenopausal early-stage breast cancer: an update. Tumori 2000;86:191—4.

6. DavidsonN.E.etal.Effectofchemohor- monal therapy in premenopausal, node- positive, receptor-positive breast cancer: an Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101). Breast 1999;8:232—3. Abstr. 069.

DavidsonN.E.etal.Effectofchemohor- monal therapy in premenopausal, node- positive, receptor-positive breast cancer: an Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101). Breast 1999;8:232—3. Abstr. 069.

7. BiancoA.R.etal.TheMam-1GOCSI trial : a randomised trial with factorial design of chemo-endocrine adjuvant treatment in node-positive (N+) early breast cancer (ebs). Proc ASCO 2001;20:27a. Abstr. 104.

BiancoA.R.etal.TheMam-1GOCSI trial : a randomised trial with factorial design of chemo-endocrine adjuvant treatment in node-positive (N+) early breast cancer (ebs). Proc ASCO 2001;20:27a. Abstr. 104.